Inspirna

About:

Inspirna is a biotechnology company developing drugs for the treatment of cancer.

Top Investors: Alexandria Venture Investments, Sands Capital Ventures, Novo Holdings, WuXi AppTec, Vivo Capital

Description:

Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs are first-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2)

Total Funding Amount:

$145M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)inspirna.com

Founders:

Masoud Tavazoie, Saeed Tavazoie, Shahram Seyedin-Noor, Sohail Tavazoie

Number of Employees:

11-50

Last Funding Date:

2022-07-11

IPO Status:

Private

Industries: